The stem bark of Magnolia obovata THUNB. (Magnoliaceae) has been used as traditional medicine for the treatment of gastrointestinal disorders, anxiety, and allergic diseases including bronchial asthma in Korea, Japan, and China.
and neurotrophic activities. 9) As a part of our continuing study on cytotoxic compounds from natural sources, two new lignans along with 11 known compounds were isolated from M. obovata. This paper deals with the isolation and structure elucidation of these compounds, as well as their cytotoxic activity against the HeLa (cervical epitheloid carcinoma), A549 (human nonsmall lung), and HCT116 (human colorectal carcinoma) cancer cell lines.
Repeated chromatography of the hexane-and EtOAc-soluble fractions of MeOH extracts from the stem bark of M. obovata on silica gel and YMC-pack RP-C 18 columns led to the isolation of 13 compounds (1-13). Among them, 11 known compounds were identified, as follows: fargesone C (3), 10) 4-methoxyhonokiol (4), 11) magnolol (5), 12) honokiol (6), 12) obovatol (7), 13) syringin (8), 14) b-sitosterol (9), 15) daucosterol (10), 15) magnaldehyde B (11), 12) magnolignan C (12), 12) and magnaldehyde E (13). C-NMR spectra of 1 were quite similar to those of 4-methoxyhonokiol (4), except for the presence of an a,b-unsaturated aldehyde group in 1. Longrange correlations between d H 7.92 (H-7) and d C 159.0 (C-4), and d H 6.84 (H-8) and d C 123.6 (C-3) indicated that an a,b-unsaturated aldehyde group was located at C-3 instead of an allyl group in 4-methoxyhonokiol (4) (Fig. 2) . On the basis of the above evidence, compound 1 was established as 5Ј-allyl-2Ј-hydroxyphenyl-4-methoxy-3-cinnamic aldehyde. -8) , confirmed that the allylphenol was linked to the coumarin moiety by C-8 ( Fig. 2) . Therefore, the structure of 2 was elucidated as 6-allyl-8-(5Ј-allyl-2Ј-hydroxyphenyl)coumarin, and was named coumanolignan.
Compounds 1-8, 11, 12, and 13 were tested in vitro for their cytotoxic activities against the HeLa, A549, and HCT116 cancer cell lines ( a) IC 50 is defined as the concentration that resulted in a 50% decrease in cell number and the results are meansϮstandard deviation of three independent replicates. b) The IC 50 greater than 30 mg/ml was considered to be no cytotoxicity. c) Positive control substance.
Experimental
Melting points were measured by using an Electrothermal apparatus. Optical rotation was determined on a JASCO DIP-100 KUY polarimeter. UV spectra were obtained with a Beckman Du-650 UV/VIS recording spectrophotometer. IR spectra were recorded on a Jasco Report-100 infrared spectrometer. Mass were carried out with a JEOL JMS-700 Mstation mass spectrometer.
1 H-NMR (300 MHz) and 13 C-NMR (75 MHz) were recorded on Bruker DRX300 and JEOL 400 spectrometers. Two-dimensional (2D) NMR experiments (HMBC) were recorded on a Bruker Avance 500 spectrometer. For column chromatography, silica gel (Kieselgel 60, 70-230 mesh and 230-400 mesh, Merck) was used. Thin layer chromatography (TLC) was performed on precoated silica gel 60 F254 plates (0.25 mm, Merck).
Plant Material The dried stem bark of Magnolia obovata was purchased from Uchida Co., Ltd., Tokyo, Japan on March 2005. The plant was identified by one of the authors, K. Bae. The voucher specimen (CNU-594) was deposited at the herbarium of the College of Pharmacy, Chungnam National University, Daejeon, Korea.
Extraction and Isolation The dried stem bark of Magnolia obovata (20 kg) was extracted with methanol (MeOH) three times under reflux for 4 h. The MeOH solutions were combined, filtrated, and concentrated to yield a MeOH extract (4000 g). The MeOH extract (4000 g) was suspended in distilled water and fractionated with hexane, EtOAc and BuOH to give hexane (1000 g), EtOAc (1200 g) and BuOH-soluble fractions (800 g), successively. The hexane-soluble fraction was chromatographed over a silica gel column eluting with hexane-EtOAc (100 : 0 to 50 : 50) to afford nine fractions (H1-H9). Fraction H2 was chromatographed on a silica gel column eluting with hexane-EtOAc (100 : 1 to 50 : 1) to give 9 (700 mg). Fraction H3 was chromatographed on a silica gel column eluting with hexane-EtOAc (100 : 1 to 20 : 1) to give compound 4 (8.5 g). Fraction H4 was chromatographed on a silica gel column eluting with hexane-EtOAc (100 : 1 to 20 : 1) to give compound 7 (5 g). Fraction H9 was subjected to a silica gel column eluting with hexane-EtOAc (50 : 1 to 10 : 1) to give three subfractions (H9.1-H9.3). Subfraction H9.2 was subjected to a silica gel column eluting with hexane-EtOAc (50 : 1 to 10 : 1) to give 5 (80 g) and 6 (50 g). The EtOAc-soluble fraction was chromatographed over a silica gel column eluting with CHCl 3 -MeOH (100 : 1 to 2 : 1) to afford nine fractions (E1-E9). Subfraction E4 was chromatographed over a silica gel column eluting with CHCl 3 -MeOH (20 : 1 to 10 : 1) to give 10 (200 mg). Subfraction E6 was chromatographed over a silica gel column eluting with CHCl 3 -MeOH (20 : 1 to 10 : 1) to give three subfractions (E6.1-E6.3). Subfraction E6.1 was subjected to HPLC [YMC-pack ODS-A, MeOH-H 2 O (40 : 60)] to yield 2 (4 mg, t R 60 min), 3 (2 mg, t R 80 min), and 1 (8 mg, t R 100 min), respectively. Subfraction E6.3 was subjected to a silica gel column using CHCl 3 -MeOH (20 : 1 to 5 : 1) to give 11 (300 mg), 12 (200 mg), and 13 (30 mg). Fraction E8 was subjected to a silica gel column using CHCl 3 -MeOH (20 : 1 to 5 : 1) to give four subfractions (E8.1-E8.4). Subfraction H8.2 was chromatographed on a silica gel column eluting with hexane-EtOAc (50 : 1 to 10 : 1) to obtain crude powder, which was purified with crystallization in CHCl 3 to give compound 8 (500 mg). Cytotoxicity Assay The cancer cell lines (HeLa, A549, and HCT116) were maintained in RPMI 1640 that included L-glutamine (JBI) with 10% FBS (JBI) and 2% penicillin-streptomycin (GIBCO). Cells were cultured at 37°C in a 5% CO 2 incubator. Cytotoxicity was measured using a modified MTT assay. Viable cells were seeded in the growth medium (180 ml) into 96-well microtiter plates (1ϫ10 4 cells per well) and incubated at 37°C in a 5% CO 2 incubator. The test sample was dissolved in DMSO and adjusted to final sample concentrations ranging from 5.0 to 100 mM by diluting with the growth medium. Each sample was prepared in triplicate. The final DMSO concentration was adjusted to Ͻ0.1%. After standing for 2 h, 20 ml of the test sample was added to each well. The same volume of DMSO was added to the control wells. Forty-eight hours after the test sample was added, MTT 20 ml was also added to each well (final concentration, 5 mg/ml). Two hours later, the plate was centrifuged for 5 min at 1500 rpm, the medium was removed, and the resulting formazan crystals were dissolved with DMSO 150 ml. The optical density (O.D.) was measured at 570 nm using a Titertek microplate reader (Multiskan MCC/340, Flow). The IC 50 value was defined as the concentration of sample which reduced absorbance by 50% relative to the vehicle-treated control.
